Neurotensin
Neurotensin, the 13 residue NTS gene product
Written by Aaron CuhaReviewed Sep 2026
Also known as: NT, NTS, Neurotensin 1-13
An endogenous 13 residue peptide with rodent analgesia data and no human trial of any cognitive or pain endpoint. The human infusion studies that do exist measured gut motility: intravenous neurotensin increased colonic contraction duration to 76% in the ascending colon, and patients discharged a median 600 mL of bowel contents 20 minutes after the infusion stopped.
Overview
Neurotensin is an endogenous 13 residue peptide, annotated in UniProt P30990 at residues 151 to 163, cleaved from a precursor that also yields neuromedin N. It is a real and well-studied neuropeptide in animal neuroscience, with roles proposed in analgesia, thermoregulation, blood pressure and the pathophysiology of schizophrenia.
It appears in consumer peptide settings as a pain or mood compound. The published human record supports neither.
What there is in humans is a body of gastrointestinal physiology work from the 1980s. Intravenous neurotensin was infused into healthy volunteers and patients and its effects on gut motility were measured. It increased colonic motility, changed duodenal and jejunal motility from a fasting pattern to a fed pattern, altered lower oesophageal sphincter pressure, and increased blood flow in adipose tissue. Every subject in the colonic motility study reported an increased sensation of intestinal movement, and the patients discharged a median 600 mL of bowel contents twenty minutes after the infusion stopped. That is the clearest picture available of what happens when a human is given intravenous neurotensin.
The analgesia work is entirely in rodents, and the field has largely moved away from the peptide itself for a specific reason: neurotensin does not cross the blood-brain barrier in useful amounts, and NTSR1 agonism in animals brings hypotension and hypothermia with it. So the medicinal chemistry effort goes into brain-penetrant biased and allosteric modulators rather than the peptide. A 2025 Cell paper reporting an arrestin-biased allosteric modulator of NTSR1 that relieved acute and chronic pain is that programme, and it is rodent work on a different molecule.
A ClinicalTrials.gov query returns no interventional trial of neurotensin or a neurotensin agonist for pain.
Mechanism of action
Proposed for the uses it is sold for, demonstrated for the ones it is not. Neurotensin acts at NTSR1 and NTSR2, G protein-coupled receptors, and at the sortilin-related NTSR3. Central NTSR1 agonism in rodents produces analgesia, and also hypotension and hypothermia, which is the coupling that has blocked therapeutic development. Peripherally, the human infusion studies demonstrate effects on gastrointestinal motility and regional blood flow. The critical delivery fact is that neurotensin does not cross the blood-brain barrier in useful amounts, so a peripherally administered dose cannot reach the central receptors that the analgesia hypothesis depends on.
Human evidence
Neurotensin has been given to human beings, in a handful of gastrointestinal physiology experiments from the 1980s. None of them measured pain, mood or cognition.
- Intravenous neurotensin at 12 pmol/kg per minute for 30 minutes increased colonic motility; motility index rose from 870 to 4500 in the ascending colon. All subjects reported increased sensation of intestinal movement; patients discharged a median 600 mL of bowel contents 20 minutes after infusion (PMID 3940251).
- A neurotensin analogue infusion altered blood flow in human adipose tissue (PMID 7180527).
- Further human infusion work measured antroduodenal motor response and lower oesophageal sphincter pressure, all gastrointestinal endpoints.
- No interventional trial of neurotensin or a neurotensin receptor agonist for pain is registered on ClinicalTrials.gov.
- No human trial of neurotensin has used a cognitive endpoint, an analgesia endpoint or a mood endpoint.
- The only clinically tested molecule at this receptor is an antagonist, SR48692, studied in ovarian cancer (PMID 28790113), which is opposite pharmacology for a different disease.
What this does not tell you: These studies establish that intravenous neurotensin in a human produces measurable gut and vascular effects. They establish nothing about the central nervous system, because neurotensin does not cross the blood-brain barrier in useful amounts and none of them attempted a central endpoint. There is no human safety dataset for repeated administration, no pharmacokinetic characterisation resolved in this pass, and no dose-finding work for any central indication.
Reading the research record
Neurotensin is a good illustration of a specific failure mode in peptide marketing: taking an important endogenous neuropeptide and treating its importance as evidence that supplementing it does something.
Neurotensin genuinely matters in neuroscience. It has a real relationship to dopamine signalling, a real literature in schizophrenia, and real analgesic activity when applied centrally in rodents. None of that is disputed here.
The problem is the delivery step, and it is not a detail. A peripherally administered peptide that does not cross the blood-brain barrier cannot produce a central effect, and the entire case for neurotensin as a pain or mood compound is central. This is exactly why the field spent the last decade building brain-penetrant biased and allosteric modulators of NTSR1 instead of using the peptide, and the 2025 Cell paper is the product of that effort. It is rodent work on a molecule that is not neurotensin.
There is a second reason the field moved on. NTSR1 agonism in animals produces analgesia coupled to hypotension and hypothermia. Separating those is the whole design problem. A consumer-facing analgesia claim ignores both the delivery problem and the coupling problem.
What human data exist are not about any of this. They are about the colon.
A cognitive endpoint is a measured one: a validated test of working memory, processing speed, attention, executive function or episodic recall, administered before and after, against a control group who did not know which arm they were in. None of the compounds in this batch has ever been tested that way. Rating scales of fatigue, global clinical impression, anxiety or hyperphagia are not cognitive endpoints, and neither is a hormone level. This matters because the marketing for several of these compounds describes focus, clarity and mental energy, and the underlying studies measured none of those things.
The evidence, charted
Fig. 1 · evidence composition
2of 4 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 1982 to 2025, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Human1986
Neurotensin increases colonic motility
What intravenous neurotensin does in a human. Six healthy volunteers (rectosigmoid) and seven patients (ascending colon and splenic flexure). Neurotensin at 12 pmol/kg per minute infused for 30 minutes increased contraction duration to 76% in the ascending colon and 46% in the rectosigmoid, with the motility index rising from 870 to 4500 in the ascending colon and from 332 to 1700 in the rectosigmoid. Motor activity did not change at the splenic flexure. All subjects reported increased sensation of intestinal movement, and the patients discharged a median 600 mL of bowel contents 20 minutes after the infusion stopped.
Gastroenterology - Human1982
Blood flow in human adipose tissue after infusion of (Gln4)-neurotensin
A second human infusion study, measuring regional blood flow in adipose tissue after a neurotensin analogue. Reported here because it is part of the small set of experiments in which neurotensin was actually given to human beings, and because like the rest of that set it measured peripheral physiology rather than pain or cognition.
Acta Physiologica Scandinavica - Animal2025
Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain
Rodents, and not neurotensin. This is a biased allosteric modulator of NTSR1, a different molecule designed to separate analgesia from the hypotension and hypothermia that accompany conventional NTSR1 agonism. It is the current state of the field and it is preclinical. Citing it as evidence for neurotensin itself would attribute a designed small molecule's rodent result to the native peptide.
Cell - Review2001
The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs
The review establishing neurotensin's place in schizophrenia research, where it is studied as an endogenous modulator interacting with dopamine systems and as a possible mediator of antipsychotic action. This is the basis of neurotensin's reputation as a CNS peptide, and it is a hypothesis about endogenous signalling rather than evidence for administering the peptide.
Biological Psychiatry
Frequently asked questions
Does neurotensin relieve pain?
In rodents, when applied centrally, yes. In humans, nobody has tested it. There is no registered interventional trial of neurotensin or a neurotensin receptor agonist for pain, and the human studies in which neurotensin was actually infused measured gut motility and blood flow.
What happens if you inject neurotensin?
The published human answer is gastrointestinal. In the one detailed infusion study, colonic contraction duration rose sharply, every subject reported increased sensation of intestinal movement, and the patient group discharged a median 600 mL of bowel contents twenty minutes after the infusion stopped. That is what was measured, in humans, at 12 pmol/kg per minute for half an hour.
Why has no one developed neurotensin as a drug?
Two reasons, both structural. It does not cross the blood-brain barrier in useful amounts, so a peripheral dose cannot reach the central receptors the analgesia hypothesis depends on. And NTSR1 agonism in animals brings hypotension and hypothermia along with the analgesia. The field's response has been to design brain-penetrant biased and allosteric modulators instead of using the peptide.
Is there a neurotensin drug in trials?
Not an agonist. The only clinically tested molecule at this receptor located in this pass is SR48692, an NTSR1 antagonist, and it was studied in ovarian cancer rather than in pain or any CNS condition. That is opposite pharmacology aimed at a different disease.
Does neurotensin do anything for focus or mood?
No controlled trial has measured a cognitive or mood endpoint with neurotensin in humans. Its reputation as a CNS peptide comes from its endogenous relationship with dopamine systems and from schizophrenia research, which is a hypothesis about what the body's own neurotensin does, not evidence about administering it.